SYABD Stock Overview
Provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SYNLAB AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €10.36 |
| 52 Week High | €10.10 |
| 52 Week Low | €8.68 |
| Beta | 0.90 |
| 1 Month Change | 1.57% |
| 3 Month Change | -12.65% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -43.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| SYABD | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | -1.6% | 3.3% | 1.0% |
| 1Y | n/a | -27.6% | 6.7% |
Return vs Industry: Insufficient data to determine how SYABD performed against the UK Healthcare industry.
Return vs Market: Insufficient data to determine how SYABD performed against the UK Market.
Price Volatility
| SYABD volatility | |
|---|---|
| SYABD Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: SYABD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SYABD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 23,538 | Mathieu Floreani | www.synlab.com |
SYNLAB AG provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe. The company offers medical and veterinary diagnostics services. SYNLAB AG was founded in 1998 and is headquartered in Munich, Germany.
SYNLAB AG Fundamentals Summary
| SYABD fundamental statistics | |
|---|---|
| Market cap | €2.27b |
| Earnings (TTM) | €89.35m |
| Revenue (TTM) | €2.62b |
25.4x
P/E Ratio0.9x
P/S RatioIs SYABD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYABD income statement (TTM) | |
|---|---|
| Revenue | €2.62b |
| Cost of Revenue | €604.92m |
| Gross Profit | €2.01b |
| Other Expenses | €1.92b |
| Earnings | €89.35m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
| Earnings per share (EPS) | 0.41 |
| Gross Margin | 76.87% |
| Net Profit Margin | 3.42% |
| Debt/Equity Ratio | 39.0% |
How did SYABD perform over the long term?
See historical performance and comparison